Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.

[1]  F. de Longueville,et al.  Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes , 2004, Cancer Research.

[2]  M. Mendiola,et al.  Molecular characterization of ovarian cancer by gene-expression profiling. , 2010, Gynecologic oncology.

[3]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[4]  M. Gottesman,et al.  Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. , 2011, Molecular pharmaceutics.

[5]  N. Cheong,et al.  Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration , 2008, Leukemia.

[6]  Bin Wang,et al.  Systematic Evaluation of Three microRNA Profiling Platforms: Microarray, Beads Array, and Quantitative Real-Time PCR Array , 2011, PloS one.

[7]  F. de Longueville,et al.  ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[8]  R. Koch,et al.  ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug , 2009, Haematologica.

[9]  P B Laub,et al.  Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. , 1997, Cancer research.

[10]  L. Wessels,et al.  Do predictive signatures really predict response to cancer chemotherapy? , 2010, Cell cycle.

[11]  H Okamura,et al.  Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability , 2005, British Journal of Cancer.

[12]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[13]  I. Pastan,et al.  Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. , 1998, Cancer research.

[14]  C. D. Salcido,et al.  Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. , 2010, Journal of the National Cancer Institute.

[15]  Jean-François Ethier,et al.  Reproductive Biology and Endocrinology Open Access Animal Models of Ovarian Cancer , 2022 .

[16]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[17]  Gabriel S. Eichler,et al.  Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database , 2009, Molecular Cancer Therapeutics.

[18]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.

[19]  Brendan Borrell,et al.  How accurate are cancer cell lines? , 2010, Nature.

[20]  T. Efferth,et al.  Chemotherapy-induced resistance by ATP-binding cassette transporter genes. , 2007, Biochimica et biophysica acta.

[21]  F. Murray-Zmijewski,et al.  A complex barcode underlies the heterogeneous response of p53 to stress , 2008, Nature Reviews Molecular Cell Biology.

[22]  M. Gottesman,et al.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. , 2003, Cancer research.

[23]  C. Wolf,et al.  Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient , 1987, International journal of cancer.

[24]  John Quackenbush Microarray analysis and tumor classification. , 2006, The New England journal of medicine.

[25]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[26]  D. Green,et al.  Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.

[27]  B. Vanderhyden,et al.  Models of ovarian cancer—Are we there yet? , 2005, Molecular and Cellular Endocrinology.

[28]  Richard Simon,et al.  Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. , 2008, European journal of cancer.

[29]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[30]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[31]  F. Lee,et al.  Apoptotic pathways of epothilone BMS 310705. , 2003, Gynecologic oncology.

[32]  T. Langmann,et al.  Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. , 2006, Clinical chemistry.

[33]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[34]  F. de Longueville,et al.  DualChip® microarray as a new tool in cancer research , 2006, Expert review of molecular diagnostics.

[35]  T. Barrette,et al.  Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. , 2007, Neoplasia.

[36]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[37]  M. Gottesman,et al.  Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. , 2011, Current pharmaceutical biotechnology.

[38]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[39]  F. Lee,et al.  BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[41]  S. Cannistra,et al.  Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.

[42]  F. de Longueville,et al.  Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia , 2006, Molecular Cancer Therapeutics.

[43]  H. Parkinson,et al.  A global map of human gene expression , 2010, Nature Biotechnology.

[44]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Chuang,et al.  Transcriptional Regulation by p53 , 1995, The Journal of Biological Chemistry.